SynAct Pharma - Initiation of coverage - Many moving parts
SynAct Pharma is a development-stage biotech company focusing on rheumatoid arthritis (RA), with scope for potential indications in other inflammatory diseases. We believe two positive data readouts in September/October could pave the way for a large out-licensing deal. We initiate coverage with a BUY and SEK170 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.